Humacyte publishes preclinical data on CTEV for CABG; human study planned

Humacyte, Inc. announced the publication of preclinical results assessing its coronary tissue engineered vessel (CTEV) as a graft in coronary artery bypass surgery (CABG) in a non-human primate model. According to the company, the CTEV remained open (patent) for six months, recellularized with host …